|
gptkbp:instance_of
|
gptkb:Antihero
|
|
gptkbp:administered_by
|
intravenous injection
|
|
gptkbp:approves
|
gptkb:2000
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Angiomax
|
|
gptkbp:chemical_formula
|
C20 H25 N3 O5 S
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:clinical_use
|
during coronary angioplasty
|
|
gptkbp:compatibility
|
other anticoagulants
calcium-containing solutions
|
|
gptkbp:contraindication
|
active bleeding
|
|
gptkbp:dosage_form
|
solution for injection
|
|
gptkbp:duration
|
up to 24 hours
as needed
|
|
gptkbp:formulation
|
sterile solution
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Angiomax
|
|
gptkbp:indication
|
percutaneous coronary intervention
|
|
gptkbp:ingredients
|
gptkb:bivalirudin
|
|
gptkbp:interacts_with
|
NSAIDs
antiplatelet agents
|
|
gptkbp:invention
|
patented
generic available
|
|
gptkbp:is_monitored_by
|
hemoglobin levels
a PTT levels
hematocrit levels
|
|
gptkbp:market_position
|
available in the US
available in Canada
available in Europe
|
|
gptkbp:marketed_as
|
gptkb:The_Medicines_Company
|
|
gptkbp:mechanism_of_action
|
direct thrombin inhibitor
|
|
gptkbp:packaging
|
vial
|
|
gptkbp:pharmacokinetics
|
rapid onset of action
short half-life
|
|
gptkbp:provides_guidance_on
|
gptkb:American_Heart_Association
gptkb:American_College_of_Cardiology
|
|
gptkbp:related_products
|
gptkb:argatroban
gptkb:heparin
|
|
gptkbp:research
|
randomized controlled trials
observational studies
meta-analyses
|
|
gptkbp:rounds
|
renal
|
|
gptkbp:route_of_administration
|
intravenous
|
|
gptkbp:safety
|
monitor renal function
|
|
gptkbp:side_effect
|
gptkb:anemia
headache
nausea
bleeding
hypotension
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:treatment
|
decreased mortality
improved coronary blood flow
reduced thrombotic events
|
|
gptkbp:used_for
|
preventing blood clots
|
|
gptkbp:weight
|
441.56 g/mol
|
|
gptkbp:bfsParent
|
gptkb:The_Medicines_Company
|
|
gptkbp:bfsLayer
|
7
|